Please login to the form below

Not currently logged in


This page shows the latest IOmet news and features for those working in and with pharma, biotech and healthcare.

Merck & Co buys another immuno-oncology target

Merck & Co buys another immuno-oncology target

Other deals have included the acquisitions of IOmet last year, cCAM Biotherapeutics in 2015 and OncoEthix a year earlier.

Latest news

  • Merck & Co buys IOmet to boost immuno-oncology tech Merck & Co buys IOmet to boost immuno-oncology tech

    Merck &Co buys IOmet to boost immuno-oncology tech. Reports suggest it paid up to £280m for the Scottish biopharma company. ... IOmet will become a wholly owned subsidiary of Merck after the transaction goes through, according to Merck.

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...